Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol vs Metoprolol Succinate in HFrEF with ICD
NCT06964464Phase 4Recruiting
- Sponsor
- University of Rochester
- Start
- Aug 2025
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carvedilol in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University of Rochester. Primary endpoint: First Occurrence of ICD Therapy, Cardiovascular Hospitalization, or Cardiovascular Death at 3 years. Started Aug 2025; status: recruiting.
02
Drugs
carvedilol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06964464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964464.